康龙化成(300759.SZ)公告称，公司拟出资13.46亿元购买无锡佰翱得生物科学股份有限公司82.54%的股 份，其中购买关联方北京康君宁元、宁波康君仲元、宁波煜沣创业投资合伙企业和北京君联惠康持有的 目标公司股份，以及收购其他非关联方持有的目标公司股份。本次交易的资金来源为银行并购贷款和部 分自有资金，完成后佰翱得及其控制的全部子公司将纳入公司合并报表范围。 ...

康龙化成（北京）新药技术股份有限公司 2025 年第三季度报告 证券代码：300759 证券简称：康龙化成 公告编号：2025-061 康龙化成（北京）新药技术股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 康龙化成（北京）新药技术股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 3,64 ...

Core Viewpoint - The stock of Kanglong Chemical (03759.HK) has increased by over 5%, indicating positive market sentiment and trading activity [1] Company Summary - Kanglong Chemical's stock price rose by 5.43%, reaching HKD 25.26 [1] - The trading volume for Kanglong Chemical was reported at HKD 45.11 million [1]

Core Insights - 康龙化成's stock increased by over 5%, reaching 25.26 HKD with a trading volume of 45.11 million HKD [1] Group 1: Partnership and Collaboration - On October 23, 康龙化成 announced a framework agreement with City University of Hong Kong, set to be signed on October 17, 2025, aimed at talent cultivation and promoting digital medicine innovation [1] - The collaboration intends to leverage both parties' strengths in academia and industry resources to accelerate the development of digital healthcare, biomedicine, and life sciences solutions [1] - The partnership is expected to create long-term social and economic benefits for Hong Kong and mainland China [1] Group 2: Institutional Initiatives - City University of Hong Kong has been promoting innovation and entrepreneurship in digital medicine since 2021, having established the HK Tech300 program that has nurtured over 1,000 startup teams [1] - Starting in 2024, the university will launch the CityU Digital Medicine Research Institute, collaborating with renowned global universities, medical schools, clinical partners, and healthcare technology investors [1] Group 3: Company Operations - 康龙化成 operates in China, the United States, and the United Kingdom, employing over 22,000 staff [1] - The company provides new drug development solutions to partners in North America, Europe, Japan, and China [1]

Group 1 - The core point of the news is that Kanglong Chemical has seen a stock price increase of 5.06% on October 24, reaching 33.03 yuan per share, with a total market capitalization of 58.734 billion yuan [1] - Kanglong Chemical's stock has risen for four consecutive days, with a cumulative increase of 4.7% during this period [1] - The company, established on July 1, 2004, specializes in drug research, development, and production services, with its main revenue sources being laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1] Group 2 - According to data, Huazhang Fund has a significant holding in Kanglong Chemical, with the Huazhang Guozheng Biomedicine ETF (159508) reducing its holdings by 6,700 shares in the second quarter, now holding 70,400 shares, which constitutes 4.3% of the fund's net value [2] - The fund has realized a floating profit of approximately 111,900 yuan today, with a floating profit of 99,200 yuan during the four-day stock price increase [2] - The Huazhang Guozheng Biomedicine ETF was established on June 29, 2023, with a current scale of 40.1303 million yuan and has recorded a year-to-date return of 15.27% [2]

Core Insights - 康龙化成's stock increased by over 5%, reaching 25.26 HKD with a trading volume of 45.11 million HKD [1] Group 1: Partnership and Collaboration - On October 23, 康龙化成 announced a framework agreement with City University of Hong Kong, aimed at talent cultivation, digital medicine innovation, and knowledge sharing [1] - The collaboration seeks to accelerate the transformation of promising digital healthcare, biopharmaceutical, and life science technology solutions, benefiting both Hong Kong and mainland China [1] Group 2: Institutional Initiatives - City University of Hong Kong has been promoting innovation and entrepreneurship in digital medicine since 2021, establishing the HK Tech 300 program, which has nurtured over 1,000 startup teams [1] - Starting in 2024, the university will launch the CityU Digital Medicine Research Institute, collaborating with renowned global universities, medical schools, clinical healthcare partners, and medical technology investors [1] Group 3: Company Operations - 康龙化成 operates in China, the United States, and the United Kingdom, employing over 22,000 staff [1] - The company provides new drug research and development solutions to partners in North America, Europe, Japan, and China [1]

Core Viewpoint - Kanglong Chemical experienced a decline in stock price by 2.03% on October 17, 2023, with a current price of 30.45 CNY per share and a total market capitalization of 54.146 billion CNY [1] Group 1: Stock Performance - Year-to-date, Kanglong Chemical's stock price has increased by 19.41%, but it has seen a decline of 7.95% over the last five trading days and 6.22% over the last twenty days [1] - The stock's performance over the last sixty days shows an increase of 15.30% [1] Group 2: Financial Performance - For the first half of 2025, Kanglong Chemical reported a revenue of 6.441 billion CNY, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 701 million CNY [2] - Since its A-share listing, the company has distributed a total of 1.794 billion CNY in dividends, with 1.007 billion CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kanglong Chemical increased by 10.12% to 87,900 [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Group 4: Business Overview - Kanglong Chemical, established on July 1, 2004, and listed on January 28, 2019, specializes in drug research, development, and production services [1] - The company's revenue composition includes laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1]

Core Viewpoint - 康龙化成's stock increased by 4.33% on October 15, with a trading volume of 9.50 billion and a market capitalization of 557.46 billion [1] Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to drug development [2][7] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] Financial Performance - For the first half of 2025, 康龙化成 achieved a revenue of 64.41 billion, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 7.01 billion [8] - The company has distributed a total of 17.94 billion in dividends since its A-share listing, with 10.07 billion distributed in the last three years [9] Market Position and Trends - 康龙化成 is a leader in the CRO (Contract Research Organization) sector, providing comprehensive CRMO solutions for drug discovery and development, focusing on small molecule drug research [2] - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3] Digital Transformation and Innovation - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through AI and automation [3] - The integration of AI technology is expected to improve clinical service efficiency and reduce labor costs, although there may be risks related to management and technology integration [2][3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2025年10月14日 （股份代號：3759） 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年10月28日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2025年9月30日止九個月之第三季度業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 樓柏良博士 ...

Core Viewpoint - 康龙化成 (03759.HK) will hold a board meeting on October 28, 2025, to review and approve the third-quarter results for the nine months ending September 30, 2025 [1] Group 1 - The board meeting is scheduled for October 28, 2025 [1] - The meeting will focus on the financial performance of the company and its subsidiaries [1] - The results to be reviewed will cover the period ending September 30, 2025 [1]